Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zevra Therapeutics

7.85
-0.1100-1.38%
Volume:103.16K
Turnover:810.92K
Market Cap:424.81M
PE:-3.44
High:7.99
Open:7.99
Low:7.78
Close:7.96
Loading ...

Zevra Therapeutics management to meet with Cantor Fitzgerald

TIPRANKS
·
26 Mar

John Bode Bought 33% More Shares In Zevra Therapeutics

Simply Wall St.
·
23 Mar

Top Executive Makes Bold Move with Major Stock Purchase in Zevra Therapeutics!

TIPRANKS
·
22 Mar

Optimistic Buy Rating for Zevra Therapeutics Driven by Miplyffa Launch and Strategic Financial Moves

TIPRANKS
·
14 Mar

Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
14 Mar

Zevra Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
13 Mar

Zevra Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
13 Mar

Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...

GuruFocus.com
·
12 Mar

Zevra Therapeutics: Strong Financial Performance and Strategic Growth Justify Buy Rating

TIPRANKS
·
12 Mar

Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
12 Mar

Zevra Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
12 Mar

Zevra Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Mar

Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours

MT Newswires Live
·
12 Mar

Zevra Therapeutics FY 2024 GAAP EPS $(2.28) Misses $(1.99) Estimate, Sales $23.600M Beat $20.514M Estimate

Benzinga
·
12 Mar

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects

Simply Wall St.
·
10 Mar